Dr. Ann Mullally is a physician-scientist and Division Chief of Hematology. Dr. Mullally received her MD from University College Dublin, completed residency at Johns Hopkins and fellowship in hematology/oncology in the Brigham/Mass General/Dana-Farber program. Prior to moving to Stanford in 2024, Dr. Mullally was a Principal Investigator at Brigham and Women’s Hospital and a clinical faculty member at Dana-Farber Cancer Institute for approximately 10 years. Dr. Mullally is actively involved in all aspects of patient-oriented research. The overarching goal of her research is to advance the biological understanding of myeloid malignancies and to translate this into improved treatment options for patients dealing with these chronic blood cancers. Dr. Mullally is known as a passionate advocate for physician-scientists in medicine, for her outstanding mentorship of trainees and as a champion of collaborative team science.

The Mullally Laboratory studies myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). They use a range of approaches including genomics, CRISPR, single-cell technologies, as well as mouse models and cellular biology to advance the understanding of MPN biology, with the goal of translating this into improved treatment options for patients. The lab is particularly interested in early MPN pathogenesis i.e. clonal hematopoiesis, MPN stem cells, bone marrow fibrosis and developing genetic and cellular therapies to treat MPN.

Dr. Mullally’s lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN. The lab has also worked extensively on the JAK2V617F mutation, the molecular dependencies of MPN stem cells and the biology of myelofibrosis.